To systematically evaluate the clinical efficacy of Shenqi Decoction in treating myocardial infarction(MI) and elucidate the pharmacological mechanism of Ginseng Radix et Rhizoma-Notoginseng Radix et Rhizoma Herbal Pair on MI using network pharmacology.Methods:Relevant research articles were retrieved from databases including the National Knowledge Infrastructure(CNKI)，China Biology Medicine(CBM)，China Science Periodical Database(CSPD)，Chinese Citation Database(CCD)，PubMed，Cochrane Library，and Embase from database inception to December 2022.After literature screening，quality assessment，and data extraction，Meta-analysis was conducted.Active ingredients and targets of Ginseng Radix et Rhizoma and Notoginseng Radix et Rhizoma were obtained from the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform(TCMSP).MI-related targets were obtained from GeneCards，OMIM，DRUGBANK，and TTD databases.The data were imported into the String database to construct the protein-protein interaction(PPI) network.Cytoscape 3.7.1 was used to construct ingredient-target and ingredient-target-pathway networks.Gene Ontology(GO) and Kyoto Encyclopedia of Genes and Genomes(KEGG) pathway enrichment analyses were performed using the Metascape database，followed by molecular docking validation using AutoDock 4.2.Results:Nine studies involving 650 patients were included.Compared with the conventional western medicine group，Shenqi Decoction combined with conventional treatment reduced left ventricular end-diastolic diameter and low-density lipoprotein and increased ejection fraction and overall clinical effective rate.Network pharmacology indicated that Ginseng Radix et Rhizoma and Notoginseng Radix et Rhizoma had 26 active ingredients，including maackiain，fumarine，quercetin，stigmasterol，and β-sitosterol.Ginseng Radix et Rhizoma and Notoginseng Radix et Rhizoma targeted 102 potential targets related to MI，including XDH，VCAM1，TNF，and TGFB1.The biological pathways regulated by Ginseng Radix et Rhizoma and Notoginseng Radix et Rhizoma in MI treatment were found to be the AGE-RAGE signaling pathway，PI3K-AKT signaling pathway，nuclear factor kappa B(NF-κB) signaling pathway，HIF-1 signaling pathway，and cGMP-PKG signaling pathway.The molecular docking results showed that the main active ingredients quercetin，kaempferol，and β-sitosterol had good binding affinity with the target ADRB2.Conclusion:Shenqi Decoction combined with conventional western medicine treatment can improve clinical efficacy in ventricular remodeling after MI.It is inferred that Ginseng Radix et Rhizoma and Notoginseng Radix et Rhizoma mainly treat MI by regulating mitochondrial function，oxidative stress，calcium homeostasis，inflammatory responses，and inhibiting cell apoptosis，providing theoretical support for further experimental research.